U.S. Food And Drug Administration (fda)
10903 New Hampshire Avenue, Silver Spring, MD 20903
Related Posts:
FDA issued 13 warning letters in October
October 30, 2019
The U.S. Food and Drug Administration (FDA) issued 13 warning letters in October that were sent to manufacturers and other companies found to have violated FDA regulations.
Read more →
FDA reports progress in support of opioid recovery and treatment act
October 30, 2019
The U.S. Food and Drug Administration's (FDA) acting commissioner, Dr. Ned Sharpless, has released a statement on the agency’s efforts to address the opioid crisis as the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act marked its one year anniversary on Oct. 24.
Read more →
Sterilization facility closures may threaten availability of medical devices, FDA cautions
October 29, 2019
Acting commissioner of the U.S. Food and Drug Administration (FDA) Dr. Ned Sharpless recently released a statement regarding medical device availability following the closure of multiple sterilization facilities.
Read more →
FDA approved record number of generic drugs in 2018
October 24, 2019
A new report on the U.S. Food and Drug Administration's (FDA) generic drug program highlights the agency's all-time record number of approvals for fiscal year 2018.
Read more →
FDA Update: 2019 animal product recalls
October 17, 2019
The U.S. Food and Drug Administration recalled 28 animal products from January through September of 2019, the agency reported.
Read more →
FDA Update: recent animal drug approvals
October 12, 2019
Federal law dictates that drug companies can’t manufacture and market medicines for animals unless they get the approval of the U.S. Food and Drug Administration.
Read more →FDA awards $15 million grant to 12 new clinical trials for rare-disease treatments
October 9, 2019
Over the next four years, the U.S. Food and Drug Administration (FDA) will be providing more than $15 million to 12 new clinical trials. The grants will help enhance the development of medical products for patients with rare diseases – mainly those affecting children.
Read more →FDA awards more than $4.1 million for natural history studies of rare diseases
October 9, 2019
The U.S. Food and Drug Administration (FDA) is providing more than $4.1 million in the next four years to fund two natural history studies of rare diseases.
Read more →
FDA issued 19 warning letters to companies in September
October 3, 2019
The U.S. Food and Drug Administration issued 19 warning letters in September that were sent to manufacturers and other companies found to have violated FDA regulations.
Read more →
Trending
The Weekly Newsletter
Sign-up for the Weekly Newsletter from FDA Reporter.